Transforming drug development with synthetic biology and AI

• Published in: Trends in biotechnology (Regular ed.) Vol. 42; no. 9; pp. 1072 - 1075
• Main Authors: Hill, Andrew, True, Jane M., Jones, Charles H.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2024; Elsevier Limited
• Subjects: Antibiotics; Artificial Intelligence; Bacteria; Biology; Coronaviruses; COVID-19; COVID-19 - virology; COVID-19 Drug Treatment; Drug development; Drug Development - methods; Drugs; Empowerment; Enzymes; Glucose; Humans; Industrial development; Insulin; Metabolism; Metabolites; Monoclonal antibodies; Pandemics; Pharmaceutical industry; Pharmaceuticals; Power; Proteins; RNA; SARS-CoV-2 - drug effects; SARS-CoV-2 - genetics; Synthetic biology; Synthetic Biology - methods; Synthetic Biology - trends; drug development; synthetic biology; RNA; artificial intelligence
• ISSN: 0167-7799; 1879-3096; 1879-3096
• DOI: 10.1016/j.tibtech.2024.01.008

The COVID-19 pandemic has thrust RNA as a platform for drug development into the spotlight. However, identifying promising drug candidates is challenging. With advances in synthetic biology and artificial intelligence (AI) models, we can overcome this hurdle, transforming drug development and ushering in a new era in the pharmaceutical industry. The COVID-19 pandemic has thrust RNA as a platform for drug development into the spotlight. However, identifying promising drug candidates is challenging. With advances in synthetic biology and artificial intelligence (AI) models, we can overcome this hurdle, transforming drug development and ushering in a new era in the pharmaceutical industry.